Make your money go further for just 25p per day

AIM IHT

More than Money: James Fair

The picks and shovels business model has worked wonders for many British biotech companies. Abcam, for example, is one of AIM’s most successful companies. Bioventix has grown 5-fold in the last four years alone.


Fusion Antibodies is the biotech sector’s latest picks and shovels company. It develops and sells monoclonal antibodies for use in novel drugs and diagnostics equipment. Its proprietary platforms, which combine biotechnology with mathematical algorithms, are used to help pharma companies around the world develop new medicines.

We have spoken to the company’s chief financial officer James Fair. 

Sign up for more great content

Register to continue reading our content.

Get FREE access now

Already a member? Login

Fundamental Asset Management
Buy any of our portfolios with our associates.
 

FIND OUT MORE

Previous article Next article

Have your say

Log in or register to view or add comments.

For access to the top news and insights from the investment world

REGISTER FREE

Become a Champion Investor for just £90 a year.
 
 

START FREE TRIAL

More on Fusion Antibodies PLC

Coronavirus impact: 28 April - soaring share prices from this little lot

28/04/2020 · Company Insights

Announcements included an update from from Burford Capital, which saw its shares bounce strongly, but we still…


More than Money: James Fair

14/11/2019 · Podcasts

The picks and shovels business model has worked wonders for many British biotech companies. Abcam, for…


More Podcasts

More than Money: Harvey Sinclair

03/03/2020 · eEnergy

More than Money: Andrew Vaughan

25/02/2020

More than Money: Ben Crawford

19/02/2020 · CentralNic